| | Study | Sample size (T/C) | Control group intervention | Treatment group intervention | Duration (week) | Assessment of outcome |
| | Chen, 2016 [43] | 100(50/50) | CAF | XHC+CAF | 6 | Tumor response, survival time, chemotoxicity |
| | Hong, et al., 2014 [44] | 84(42/42) | TAC | XHP+TAC | 18 | Tumor response, KPS, chemotoxicity, OS, PFS |
| | Jin, et al., 2010 [45] | 60(30/30) | CAF | XHP+CAF | 6 | Symptom curative effect of TCM, CD4+, CD8+ |
| | Mao, et al., 2014 [46] | 68(34/34) | NR | XHC+Chemotherapy | 8 | Tumor response, three-year survival rate, KPS, recurrence and metastasis rate |
| | Wang, 2018 [47] | 123(64/59) | TP | XHP+TP | 12 | Tumor response, KPS, tumor marker, chemotoxicity, one-year/two-year survival rate |
| | Wang, 2015 [48] | 80(40/40) | CA | XHC+CA | 6 | Tumor response, MST, PFS, chemotoxicity, |
| | Wang, et al, 2017 [49] | 98(49/49) | CAF | XHP+CAF | 8 | Tumor response, tumor marker, CD3+, CD4+, CD4+/CD8+, coagulation function, chemotoxicity |
| | Wang, 2017 [50] | 60(26/34) | AC-T | XHC+AC-T | 24 | KPS, CD4+, CD8+, CD4+/CD8+ |
| | Wu, 2016 [51] | 90(45/45) | TEC | XHP+TEC | 18 | tumor marker, indicators of inflammatory response, CD3+, CD4+ |
| | Xu, et al., [52] | 253(128/125) | TP | XHP+TP | 3 | Tumor response, tumor marker, KPS, chemotoxicity |
| | Yue, et al., [53] | 78(39/39) | TAC | XHP+TAC | 18 | Tumor response, P53, HER2, TOPII |
| | Zhang, et al., [54] | 90(45/45) | AC4-T4 | XHC+AC4-T4 | 12 | KPS, quality of life, chemotoxicity |
| | Zhou, et al., [55] | 88(44/44) | GP | XHC+GP | 6 | Tumor response, chemotoxicity, TNF-α, VEGF, MMP-2, MMP-9 |
|
|
Notes. XHC: Xihuang capsule, XHP: Xihuang pill, TG: treatment group, CG: control group, KPS: Karnofsky performance score, OS: overall survival, PFS: progression-free-survival, and MST: median survival time.
|
